.
Abstract
OBJECTIVE: To
determine the efficacy of dalantercept, a soluble ALK1 inhibitor receptor
fusion protein, in #patients with persistent or recurrent #ovariancarcinoma and
related #malignancies.
METHODS: Eligibility
criteria included measurable disease, 1-2 prior cytotoxic regimens and GOG
performance status (PS) ≤2. Dalantercept was administered subcutaneously at 1.2 mg/kg every 3 weeks until disease progression or
development of unacceptable #toxicity. The primary null hypothesis was the
probability of response ≤0.10 and the probability of 6-month progression-free
survival without receipt of non-protocol therapy (event-free survival at 6 months, EFS6) ≤0.15,
using RECIST 1.1 criteria
No comments:
Post a Comment